Alzinova AB

Last week, we announced positive results from our phase 1b clinical trial for our Alzheimer’s vaccine candidate, ALZ-101. Following this milestone, Alzinova AB's CEO Tord Labuda shared key insights in interviews with Redeye and Carnegie, where he discussed the promising data and what it means for the future of Alzheimer’s treatment.   We’re proud to contribute to the fight against Alzheimer’s and are optimistic about the journey ahead. You can watch both interviews and learn more about the study results on our website: https://lnkd.in/d56DMaaq   Together, we’re moving closer to making a real difference for patients and their families.   #AlzheimersResearch #ClinicalTrials #Innovation #Healthcare

Alzinova AB har presenterat lovande data från sin kliniska fas Ib-studie med vaccinkandidaten ALZ-101 för behandling av Alzheimers sjukdom. En analys av data från patienter som deltagit i studien i minst 84 veckor visar på en fortsatt god tolerabilitet och säkerhetsprofil, samtidigt som en hög immunrespons har observerats hos majoriteten av patienterna. BioStock sökte vd Tord Labuda för en kommentar. #lifescience #Alzheimers

Alzinova AB will participate in the J.P. Morgan Healthcare Conference 2025, one of the most influential events in the global healthcare sector. The conference, taking place January 13–16 in San Francisco, gathers leading companies, innovators, and investors to explore the future of healthcare. CEO Tord Labuda and Business Development Director Sebastian Hansson will represent Alzinova, meeting with key stakeholders to discuss the company’s innovative approach to Alzheimer’s disease treatment, including the development of its vaccine candidate, ALZ-101. Participation in this conference is a strategically important step in advancing discussions with potential partners and exploring opportunities to further enhance the development of ALZ-101. Connect with us to learn more about Alzinova – whether you’re already familiar with our work or discovering us for the first time! https://www.alzinova.com #JPM2025 #Alzinova #Alzheimers #Alzheimersdisease #Networking #Lifescience

🌟Alzinova AB reports positive results from the phase 1b extension part of the ALZ-101 study in Alzheimer's disease🌟 We are excited to share positive outcomes from the extension phase of our phase 1b clinical study for ALZ-101, our vaccine candidate targeting Alzheimer’s disease. Key findings include: ✅ Favorable safety and tolerability ✅ A robust and long-lasting immune response, observed in over 95% of patients. ✅ Positive dose-dependent trends in cognitive and functional parameters. These results provide strong momentum as we advance preparations for a phase 2 study. We invite you to join us for a live Q&A session today at 13:00 to learn more about these exciting developments. Together, we’re working toward a future of hope for Alzheimer’s patients and their families. Learn more about the results in the press release, link in comments. ⬇️ #AlzheimerResearch #Innovation #Biotech #ALZ101 #Alzinova

We participated at Carnegies Small Cap day! Yesterday, November 28, Alzinova AB presented at Carnegie's Small Cap Day in Stockholm. Our CEO Tord Labuda shared insights on our innovative treatment for Alzheimer's, the progress of our clinical studies and our plans for the future. Did you miss the event? For our Swedish followers, you can watch our presentation here: https://lnkd.in/damU8dWc #alzheimer #alzheimerresearch

On November 28th, Alzinova AB’s CEO, Tord Labuda, will take the stage at Carnegie's SME Day to share insights about Alzinova and our mission. 🗓️ Date: November 28th ⏰ Time: 16:15 📍 Where: Tune in via the Carnegie live stream, link below Join us as we present our progress in Alzheimer's research and connect with the investor community. Don't miss it! #AlzheimersResearch #InvestorEvent #CarnegieSMEDay #Presentation

Alzinova AB har, under ledning av nye vd Tord Labuda, visionen att positionera sin amyloid-beta oligomer-specifika immunterapi som ett nytt behandlingsalternativ för Alzheimers sjukdom. Bolagets Q3-rapport som släpptes igår, tar ett naturligt avstamp i framstegen som gjorts i år, milstolpar i närtid, samt målet att inleda en fas II-studie under 2025. #lifescience #Alzheimers

Yesterday, Alzinova ABs interim report for January - September 2024 was published! Learn more about our latest achievements in the development of our vaccine candidate ALZ-101 in the ongoing phase 1b study and the overall progress in the company.   Read the full report on our website, link in the comment section.   #InterimReport #AlzheimersResearch #AlzheimersDisease

Exciting times at BIO Europe 2024! Our CEO Tord Labuda and Business Development Director Sebastian Hansson are proudly representing Alzinova AB as we connect with industry leaders and companies.   We are thrilled to share our journey and advancements in addressing Alzheimer’s disease, showcasing our portfolio that have the potential to transforming lives through innovative solutions.   Together, we are shaping the future of healthcare. Let's make a difference! 💡   #BIOEurope2024 #Alzinova #Innovation #Healthcare #AlzheimersResearch

Come meet Alzinova AB at BIO-Europe! Our CEO Tord Labuda and Business Development Director Sebastian Hansson, will be there to promote our two exciting projects; our vaccine candidate ALZ-101 and antibody ALZ-201 against Alzheimer's disease. To explore collaboration and partnership opportunities, send a meeting request through the partnering platform or contact our team via email at info@alzinova.com or send Sebastian a DM here on LinkedIn. We look forward to deepening contacts and exploring collaborations! #BIOEurope #precisionmedicine #innovation #alzheimerresearch #partnering